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Functional Mechanisms of Treg in 
the Context of Hiv infection and the 
Janus Face of immune Suppression
Jacobo López-Abente, Rafael Correa-Rocha and Marjorie Pion*
Laboratory of Immunoregulation, “Gregorio Marañón” Health Research Institute (IISGM), Madrid, Spain
Regulatory T cells (Tregs) play an important role in infections, by modulating host 
immune responses and avoiding the overreactive immunity that in the case of human 
immunodeficiency virus (HIV) infection leads to a marked erosion and deregulation of 
the entire immune system. Therefore, the suppressive function of Treg in HIV-infected 
patients is critical because of their implication on preventing the immune hyperactivation, 
even though it could also have a detrimental effect by suppressing HIV-specific immune 
responses. In recent years, several studies have shown that HIV-1 can directly infect 
Treg, disturbing their phenotype and suppressive capacity via different mechanisms. 
These effects include Foxp3 and CD25 downregulation, and the impairment of sup-
pressive capacity. This review describes the functional mechanisms of Treg to modulate 
immune activation during HIV infection, and how such control is no longer fine-tune 
orchestrated once Treg itself get infected. We will review the current knowledge about 
the HIV effects on the Treg cytokine expression, on pathways implying the participation 
of different ectoenzymes (i.e., CD39/CD73 axis), transcription factors (ICER), and lastly 
on cyclic adenosine monophosphate (cAMP), one of the keystones in Treg-suppressive 
function. To define which are the HIV effects upon these regulatory mechanisms is crucial 
not only for the comprehension of immune deregulation in HIV-infected patients but also 
for the correct understanding of the role of Tregs in HIV infection.
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iNTRODUCTiON
Human immunodeficiency virus (HIV) infection is hallmarked by a depletion of CD4+ T-cell pool 
and a persistent immune activation that may lead to a progressive degradation and senescence of 
the immune system (1, 2). Chronic immune activation is considered at present as a better predic-
tor of HIV-1 disease progression than the extent of viral replication (2, 3). Furthermore, activated 
CD4+ T cells constitute the main target of HIV infection and its subsequent active replication (4); 
therefore, the onset of systemic immune activation will be favorable for the HIV spreading and 
viral persistence. One of the keystones responsible for preventing such immune hyperactivation 
and controlling immune cell proliferation are regulatory T cells (Tregs). Tregs are a subset of CD4+ 
T cells characterized by the high surface expression of the high-affinity interleukin 2 receptor alpha 
(CD25 or IL-2-Rα) and the nuclear transcription factor forkhead box P3 (Foxp3) (5–7). In the 
majority of infectious episodes, Tregs get activated and, thus, induced to proliferate in order to 
control overreactive immunity thanks to their suppressive capacity (8). Their suppressive function is 
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achieved by several suppressor mechanisms, including  disruption 
of metabolic pathways (CD39/CD73 axis, cyclic adenosine 
monophosphate (cAMP), and ICER pathways) (9–13), modula-
tion of APC maturation and function (CTLA-4 and PD1/PD-L1-
dependent tolerogenic APC induction) (14–19), production of 
anti-inflammatory cytokines (IL-10, TGF-β, and IL-35) (20–22), 
and induction of apoptosis (via Fas/Fas-ligand pathway, gran-
zyme A/B and perforin, TRAIL, the galectin-9/TIM-3 pathway, 
or galectin-1 production) (23–27). Tregs can suppress immune 
responses and, therefore, limit collateral tissue injury; however, 
their function could be also favorable for pathogen persistence 
by suppressing antigen-specific T-cell responses (28). In fact, it 
is believed that Treg may contribute to inefficient cell-mediated 
immunity on chronic HIV infection since some studies showed 
increased Treg frequencies in such phase (29–31). However, Treg 
may also have beneficial effects by limiting immune activation 
and, hence, restricting potential targets for HIV infection, as 
well as minimizing the pathological effects resulting from HIV-
mediated immune hyperactivation (9). Such beneficial versus 
detrimental effects of Treg in HIV infection have been a subject 
of controversy in recent years (30, 32–35). In addition, the fact 
that Tregs are a subset of CD4+ T cells expressing CXCR4 and 
CCR5 coreceptors makes these cells susceptible of being infected 
by HIV, complicating even more the comprehension of the real 
role of Tregs in HIV infection. Recent findings from our group 
demonstrated that HIV can directly infect Tregs producing a 
marked deregulation on the phenotype and functionality of the 
cells (36, 37), and decreased Treg absolute counts described in 
infected patients (38–40) supports the hypothesis that Treg 
deregulation might be related to the immune hyperactivation 
present in HIV-infected patients.
The aim of this review is to provide a detailed scope of those 
mechanisms and molecules that are crucial for either Treg modu-
lation or functionality but may also play a role in HIV infection 
(CD25, Foxp3, CD39/CD73, cAMP, ICER, and CTLA-4). The 
second part of the review will focus on how HIV direct infection 
of Tregs might jeopardize each of the mechanisms described in 
the first part by suppressing the Treg cornerstone molecules: 
CD25 and Foxp3. Finally, we will discuss how HIV-mediated 
Treg deregulation might contribute to the overall immune-
hyperactivation scene characterizing HIV-infected patients and 
their clinical progression.
Treg iMMUNe-MODULATiON AND 
MeCHANiSMS OF ACTiON
CD25/iL-2 Axis, the Master Regulator in 
the Maintenance of Balanced immune 
Responses
Treg homeostatic role depends on the surface expression of the 
high-affinity interleukin 2 receptor alpha (CD25 or IL-2-Rα) 
and IL-2 uptake (41, 42), thus receiving the name of CD25/IL-2 
axis. The CD25/IL-2 axis is essential for Treg survival, expan-
sion, homeostasis and their suppressive function. Regarding 
the CD25/IL-2 axis role in Treg function, it is assumed that 
activated T cells are the main IL-2 producers; thus, there is a 
negative feedback control of immune activation through IL-2 
availability (37). As soon as the number of IL-2 secreting T 
cells and IL-2 concentration increase, Treg will react via cel-
lular expansion, uptaking the extracellular IL-2 and, thus, 
activating their suppressive function. Both Treg production of 
suppressive cytokines and IL-2 consumption by Treg are pivotal 
mechanisms to prevent an excessive T-cell expansion and to re-
establish the homeostasis of the immune system (43, 44). This 
mechanism guarantees that the relative Treg:T-effector ratio is 
continuously maintained even though the number of CD4+ 
T cells is significantly altered (41, 43). It has been shown that 
the Treg capacity to sense IL-2 is directly responsible for their 
function and IL-2 availability is an important mechanism by 
which Tregs exert their role (44). In humans, IL2RA gene poly-
morphisms affecting CD25 function have been associated with 
multiple sclerosis, type 1 diabetes, juvenile idiopathic arthritis, 
or lymphoproliferative-associated immunodeficiency (43, 45), 
highlighting the dependency of Treg in this receptor to exert 
their function. Furthermore, CD25/IL-2 signaling through 
STAT5 is essential to sustain Forkhead box P3 (Foxp3) expres-
sion on Treg (46, 47), which is a critical factor to keep Treg fate 
and function (6, 48). The CD25/IL-2 axis also plays a critical 
role in cAMP production, being cAMP a crucial regulator of 
immune cells. It has been shown that Treg activation by IL-2 
leads to a significant upregulation in the adenylyl cyclase (AC) 
activity and, hence, to the cAMP cytosolic accumulation (11). 
The high-affinity receptor, CD25, enables the Tregs to uptake 
extracellular IL-2 in advantage compared to other cells (41). IL-2 
removal by Treg will avoid the IL-2-associated downregulation 
of AC isoform 7 (AC7) in conventional T cell and, therefore, the 
reduction of intracellular cAMP levels (11). Favoring low cAMP 
levels in conventional T cells is associated with an increase in 
T  cell proliferation. The role of cAMP in immune response 
modulation will be extensively studied in following paragraphs.
In the context of HIV infection, CD4+ T cells undergo a 
marked activation followed by a status of exhaustion and senes-
cence (49). It would be expected to find an increased production 
of IL-2 due to the extended T-cell activation, which should acti-
vate the Treg response to limit an excessive activation/expansion 
of effector T cells. However, there is evidence that this mechanism 
is not working properly since it is observed that the CD4+ T cell 
pool is permanently activated, becoming finally exhausted (50) 
and the immune activation will persist in HIV-infected patients. 
Moreover, it was already described a reduction in IL-2-producing 
cells in moderate and advanced stages of HIV type-1 infection 
(51). An explanation would be that IL-2 expression is repressed in 
CD4+ T cells during chronic HIV infection due to the increased 
methylation of IL-2 promoter observed in infected patients (52). 
In addition to its role in the Treg/effector balance, IL-2 has proven 
to inhibit HIV-1 replication in cell lines by the induction of 
APOBEC3G (53). Moreover, the therapy with recombinant IL-2 
has been tested in HIV-infected patients with the goal of both to 
recover the CD4+ T cell counts and to mobilize the reservoir of 
latent virus activating the latently infected CD4+ T cells (54–56). 
However, despite a sustained increase of the CD4+ T cells count, 
these clinical trials involving recombinant IL-2 plus antiretrovi-
ral therapy (ART) did not show any clinical benefit (57). This 
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highlights that there are many factors involved and the modifica-
tion of IL-2 is not enough to control the fate of the disease.
All that points out the relevance of a deregulation in the CD25/
IL-2 axis as one of the mechanisms related to the immune imbal-
ance and subsequent hyperactivation found in HIV-infected 
patients.
Foxp3, a Determinant Factor of Treg 
identity and Functionality
Foxp3 is a crucial transcription factor determining Treg identity, 
development, and maintenance (6, 48). Expression of Foxp3 can 
also be induced and converts conventional CD4+ T cells into 
induced Treg cells (iTreg) (6). This iTreg generation could be 
observed in periphery or in vitro, and is induced by T-cell recep-
tor (TCR) stimulation in the presence of IL-2 and TGF-β. Even 
though iTreg may be able to exert suppressive function as natural 
Treg, their Foxp3 is not stabilized by epigenetic modifications 
and, therefore, its expression is finally lost in vivo (58). Decreased 
Foxp3 expression in Treg is related to the switch to a cytokine-
secreting profile characteristic from other CD4+ T  cell helper 
lineages (48). Indeed, severe attenuation or ablation of Foxp3 
expression resulted in the acquisition of the ability to produce 
effector cytokines, such as IL-2, IL-4, IL-17, TNF-α, and IFN-γ 
(48), and correct Foxp3 expression will suppress Th17 differen-
tiation by inhibiting the function of the Th17 lineage-specifying 
transcription factor retinoid-acid receptor-related orphan recep-
tor (ROR)-γt (59). Moreover, as transcription factor, Foxp3 can 
regulate gene expression of several genes, between which can 
be found CD39, adenine cyclase 9, and many others. Within 
its regulation role, it is interesting to note that Foxp3 forms a 
cooperative complex with NFAT, which is required to repress the 
cytokine IL-2 transcription and for upregulation of the cytotoxic 
T lymphocyte-associated antigen 4 (CTLA-4) and CD25 expres-
sion (60–62), both relevant markers for Treg function. In HIV 
context, Foxp3 transfection demonstrated inhibitory effects upon 
HIV transcription in primary human CD4+ T cells (63, 64). HIV 
transcriptional downregulation could be associated with NF-κB-
dependent and -independent mechanisms (63), as well as to the 
Foxp3-dependent inhibition of NFAT activity. It was shown that 
Foxp3 decreases the binding of NFAT2 to the HIV promoter 
in vivo by its capacity to sequestrate it (61, 64).
Several articles describe increased relative frequencies of 
Tregs (CD4+ T cells expressing Foxp3) in HIV-infected patients 
(29, 65). This increased Treg proportion could be explained by 
a preferential depletion of conventional CD4+ T cells or by an 
increased expansion and/or induction of Tregs (65). Due to 
the absence of appropriate markers to distinguish natural from 
induced Treg, it is difficult to know whether the inflammatory 
or hyperactivated context of HIV infection promotes the dif-
ferentiation of conventional CD4+ T cells to iTreg. Jenabian et al. 
recently demonstrated that soluble CD40-ligand (sCD40L) levels 
are increased in plasma from HIV-infected patients, and this 
sCD40L induced Treg expansion and favored Treg differentiation 
from conventional CD4+ T cells (66). Since iTregs are not able to 
maintain a long-term Foxp3 expression and suppressive activity, 
and since they can even acquire a pro-inflammatory phenotype, 
further studies on the Treg dynamics are required to understand 
the role of iTregs in the context of HIV infection.
extracellular ATP Metabolism and 
Signaling in T Cells: CD39/CD73 Axis
From among all the Treg mechanisms related to their suppres-
sive capacity, adenosine triphosphate (ATP) metabolism is one 
that is well documented. In this context, there are two essential 
players that constitute the CD39/CD73 axis. CD39 or nucleoside 
triphosphate diphosphohydrolase 1 (NTDPase 1) is an ectoen-
zyme that hydrolyzes ATP or ADP to AMP (10). This enzyme is 
expressed by a subpopulation of Treg and, orchestrated together 
with another ectonucleotidase named AMPase CD73 present on 
the Treg surface, they are able to process AMP into adenosine 
(67). Adenosine exerts immune inhibitory effects as discussed in 
following paragraphs. It is interesting to note that Foxp3 expres-
sion is directly related to adenosine production since retroviral 
transduction of CD4+ CD25− lymphocytes with Foxp3 induced 
the expression of CD39 (6, 10), a potent inhibitor of cell prolifera-
tion and indirect contributor to the high cAMP levels found in 
Treg via adenosine generation (9).
In order to understand the formation of adenosine, we will 
describe the origin and relevance of ATP, which is the CD39/
CD73 axis substrate. Extracellular ATP is released under hypoxia, 
inflammatory responses, metabolic stress, or other types of cell 
injury. The impact of extracellular ATP on the immune system 
is critical since its increase induces the activation of the inflam-
mosome and subsequent release of cytokines, such as IL-1β 
(68, 69), in response to damage-associated molecular patterns 
(DAMPS) and pathogen-associated molecular patterns (PAMPS) 
(70). Therefore, extracellular ATP is considered a danger signal 
liberated by damaged or dying cells that induces pro- and 
anti-inflammatory signals. In the context of immune chronic 
activation as in HIV infection, ATP released by activated T cells 
seems to have an autocrine effect, prolonging activation and IL-2 
secretion (71).
In contrast to ATP, adenosine exhibits anti-proliferative and 
inhibitory effects, hence giving to the CD39/CD73 activity an 
immune suppressive role (10). In fact, it was shown that induced 
Treg expressing CD39+ acquired higher suppressive capacity 
than CD39neg iTreg (72). Adenosine plays an antagonistic role on 
Treg compared to non-Treg responses by directly binding to the 
adenosine 2a receptor (A2AR), consequently inducing the ade-
nylyl cyclase activity and, therefore, increasing the intracellular 
cAMP level. ATP removal and A2AR activation elicits inhibitory 
functions in dendritic cells and activated T-cell subsets, inducing 
T-cell anergy (73); whereas in Treg, A2AR induces the generation 
of Foxp3+ Tregs (73) and enhances Treg immunosuppressive 
mechanisms (74, 75). Summing up, Treg could dampen immune 
activation as well as induce activated T-cell dysfunction through 
CD39/CD73 activity.
It is interesting to note that a study of CD39/CD73 distribution 
in Treg and conventional CD4+ T cells showed that even though 
CD39 is largely expressed on human Treg (CD4+ CD25hiFoxp3+ 
T cells), CD73 is not so widely expressed and <1% of Treg 
expressed both ectonucleotidases at their surface (76–78). One 
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hypothesis is that only few cells capable of hydrolyzing ATP to 
adenosine are necessary to induce a local suppression and that 
this pathway must be finely regulated to avoid any unwanted 
Treg-suppressive function. Moreover, it was described that CD73 
was present in cytoplasmic granules and that its expression at the 
surface of Treg might be transient, which would be another level 
of regulation of adenosine production (77, 78).
In the case of HIV infection, there is high expression of CD39 
in Treg cells, which remains unaltered even with ART (31, 79). 
CD39+ Treg frequency and number are elevated in HIV patients, 
and correlates negatively with CD4+ T-cell recovery and positively 
with plasma viral load and T-cell activation (80, 81). In addition, 
through a case-control study, a genetic variant of CD39 associated 
with lower expression of CD39 enzyme was linked to a slower 
progression to AIDS (81). Moreover, in vitro suppression assays 
demonstrated that the suppressive effect of CD39+ Treg upon 
gag-stimulated CD8+ cytokine production was partially inhib-
ited when adding CD39 blocking monoclonal antibodies (81). All 
this may highlight a negative role of CD39+ Treg in controlling 
HIV progression. However, there is still controversy regarding 
the role of CD39 in HIV infection, Schulze et al. demonstrated 
that HIV controllers were shown to have similar CD39+ Treg to 
healthy subjects (79). Additionally, it has been shown that Foxp3 
modulates the expression of CD39 at the surface of Treg and also 
regulates HIV promoter’s transcription activity. Moreover, CD39 
might also be contributing to hindering HIV infection as sug-
gested in following paragraphs.
In summary, Treg might have two contrary functions on HIV 
replication and disease progression. On the one hand, CD39 
expression may be involved in Treg-mediated suppression of 
HIV-specific responses and, thus, on disease progression. On 
the other hand, Foxp3 induce a negative effect on HIV transcrip-
tion, which could limit new particles production or induce HIV 
latency in Foxp3-expressing cells. However, one could claim that 
CD39+ Tregs may be critical for the inhibition of T-cell immune 
activation, which may reduce the niche for HIV replication 
(82, 83). In fact, blocking CD39 and, thus, inducing the decrease 
of cAMP levels in Treg were shown to abrogate the Treg-mediated 
suppression of HIV replication (84). Therefore, it is possible that 
CD39+ Foxp3+ Tregs could control HIV infection, especially 
during the first days of infection, prior to the HIV dissemination 
to the secondary lymphoid organs, phase where just a few effector 
T cells are activated (84).
CD38 and NAD+ as Precursor of 
Adenosine
Few years ago, an alternate route to producing extracellular 
adenosine was discovered. This axis had its pivotal role around 
the NAD+-glycohydrolase CD38, the 5′-ectonucleotidase CD73 
and the ecto-nucleotide pyrophosphatase/phosphodiesterase 
(PDE) CD203A (85). Leaded by CD38, main NAD+ consum-
ing enzyme (86), it has been shown that CD38/CD203A/CD73 
will transform NAD+ into adenosine (85), whose function is 
extensively described in this review. Horenstein et al. and oth-
ers demonstrated in different in vitro models that this alternate 
pathway may synergize, flank, or bypass the aforementioned 
described canonical catabolic pathway orchestrated by CD39 
(85–88). Regarding to the Treg population, it has proven to 
express CD38 (89, 90) and seems that its level of expression 
positively correlates with their suppressive function (90). Patton 
et al. demonstrated in a murine model that CD38high Tregs have 
higher suppressive capacity than CD38low Treg, which failed to 
upregulate CD73, key molecule for adenosine production, in 
both canonical and CD38 pathway. However, it is still under 
evaluation if Tregs are capable of processing NAD+ through this 
newly discovered pathway (85, 91).
Regarding to the role of CD38 in the context of HIV infection, 
this enzyme is commonly regarded as a T-cell activation marker, 
and peripheral blood CD38+ CD8 T cells have been strongly 
correlated with disease progression in untreated HIV infection 
(92, 93). It has been shown that rectal Treg frequency is positively 
related to CD38+ CD4+ and CD8+ rectal T cells in chronic HIV-
positive non-controllers (94). However, this may vary depending 
on the sampling site and time point of infection, since Tregs are 
inversely correlated to CD38+ CD8+ T cells in blood at primary 
HIV infection as others have shown (95). Summing up, CD38 
is not only a predictive marker of disease progression but also 
may be another mean for Treg to produce adenosine and exert its 
suppressive function.
iCeR and cAMP, Differential Role  
on CD4+ T-Cell Subsets
Cyclic adenosine monophosphate is a derivative of ATP. cAMP 
acts as a secondary messenger involved in many biological pro-
cesses and in regulation of immune cells, playing an important 
role on determining the balance between suppression and activa-
tion. In fact, cAMP present on conventional T cells or on Treg is 
implicated in different signaling pathways.
cAMP Is a Major Mediator of  
Treg-Suppressive Potential
In Treg, the suppressive potential has been demonstrated to 
depend on cAMP (96). Indeed, Tregs tend to preserve their high 
levels of intracellular cAMP. To partially explain the maintenance 
of such high levels, it has been shown in murine nTreg cells that 
the expression of the cAMP degrading PDE3b is reduced by direct 
binding of Foxp3 to the PDE3B promoter (97), limiting Treg 
intracellular cAMP degradation. Treg can induce the intracellular 
cAMP production by the sequential processing of extracellular 
ATP to adenosine by the CD39/CD73 axis, inducing adenylyl 
cyclase activity in the target cell through A2AR (69, 75, 78). The 
importance of A2AR in mediating the inhibition of inflammation 
was demonstrated in A2AR null mice, where the transgenic ani-
mals suffered of massive tissue destruction and systemic inflam-
mation due to their inability to control inflammation (98). It is 
interesting to note that A2AR engagement using an agonist not 
only was able to induce TGF-β and Foxp3 expression on activated 
T cells (73) but was also able to increase the intracellular cAMP 
level on purified Treg. Therefore, A2AR engagement increases 
the number of Tregs, activates their immunoregulatory activity, 
and allows iTreg generation. Thus, it has already been described 
how IL-2R, A2AR activation, and Foxp3 expression contribute 
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to the “supraphysiological” intracellular levels of cAMP found in 
Treg. Treg can mediate cAMP transfer to activated CD4+ T cell 
and dendritic cells through gap junction intercellular commu-
nications (GJICs) (75, 96, 99). The formation of such channels 
composed by two opposing hemichannels allows the connexion 
between adjacent cells (100), therefore increasing intracellular 
cAMP in the target cells (96). In the case of DCs, cAMP induces 
the rapid downregulation of the co-stimulatory molecules CD80 
and CD86, preserving their tolerogenic phenotype and indirectly 
regulating T-cell function (101). Furthermore, cAMP induction 
in DCs, following activation of adenosine and prostaglandin 
receptors, downregulates NF-κB activity not only decreasing the 
DC production of cytokines, such as TNF-α, IL-6, IL-12, IL-1α, 
and chemokines MCP-1 and MIP-1α, but also increasing the 
production of the anti-inflammatory cytokine IL-10 (102).
cAMP and ICER, Key Modulators of  
Conventional T-Cell Function
On conventional T cells, A2AR expression is induced after TCR 
stimulation via NF-AT-signaling pathway (73). This upregulation 
of A2AR expression was followed by an increase in intracellular 
cAMP level, demonstrated by the use of an A2AR-specific 
agonist (73). cAMP activation triggers a number of down-
stream signaling cascades on conventional CD4+ T cells. The 
main stream pathway is the activation of the cAMP-dependent 
protein kinase-A (PKA), which is involved in the regulation of 
several physiological processes as modulation of ion channels 
and transcription of genes (103). PKA will activate the transcrip-
tion factor CREB by phosphorylation, consequently triggering 
the interaction of phospho-CREB and the nuclear protein CBP, 
which is a coactivator that augments the activity of phosphoryl-
ated CREB. Afterwards, CREB binds to a DNA element known 
as the cAMP-regulated enhancer element (CRE) activating the 
transcription of cAMP-responsive elements (104). Thus, con-
sequently triggering the formation of the induced cAMP early 
repressor (ICER), which is generated from the 3′ region of the 
gene encoding the cAMP response element modulator (CREM) 
due to alternative promoter binding (105). ICER will bind to 
CRE and thereby represses the activity of its own promoter, 
constituting then a negative auto-regulatory loop (105). In fact, 
ICER was considered a master regulator of the cAMP response, 
inhibiting T-cell function, most specifically downregulating IL-2 
production on effector T cells, critical for T-cell growth (12, 106). 
When ICER is transgenically over-expressed in mice T  cells, 
these lymphocytes present proliferative defects hallmarked by 
decreased IL-2 production (13), similar to the effect on IL-2 
production resulting from the co-culture of CD4+ T cells and 
nTreg (12). In parallel, when intracellular cAMP levels rise on 
effector T cells, NFAT/ICER complexes are formed; this will play 
an important role on suppressing NFAT activity via its sequestra-
tion. Therefore NFAT will not be accessible for the cytokines and 
chemokines transcriptional induction, such as IL-2, IL-4, TNF-α, 
IL-13, MIP-1α, MIP-1β, and GM-CSF (107, 108). Taken together, 
all this information highlights the critical role of ICER induced 
by cAMP transferred from nTreg and which mediates suppres-
sion of several immune mediators, especially IL-2 production on 
effector T cells (109) and, hence, demonstrates the relevance of 
the cAMP/PKA pathway in suppressing T-cell responses.
HIV Enhances Intracellular cAMP,  
a Double-Edged Immune Sword
It has been shown that intracellular cAMP levels of T cells from 
HIV-infected patients are higher than those from healthy subjects 
(110, 111). In vitro studies corroborated the presence of higher 
cAMP levels in HIV-infected primary T cells and T cell lines com-
pared to uninfected cells (111, 112). Interestingly, HIV infection 
was not required to increase intracellular cAMP, since the T cell 
treatment with the envelope glycoprotein gp120 was already suf-
ficient to elicit such response and activate cAMP/PKA pathway 
through Treg function (113, 114). However, the mechanisms 
underlying gp120-mediated response are still unresolved. The 
potential benefit or hazard of intracellular cAMP in the context 
of HIV infection is still a matter of debate.
It has been shown that cAMP/PKA pathway can inhibit 
HIV-specific T-cell responses and such inhibition will favor viral 
replication. Besides inhibiting immune responses, HIV induces 
impairment on proliferation in CD4+ and CD8+ T-cell subsets, 
through the activation of the cAMP/PKA pathway by viral pro-
teins. In fact, the pre-treatment of the cells with a PKA inhibitor 
prevented the induction of anergy (112), highlighting the negative 
role of high intracellular cAMP resulting from HIV infection. In 
a similar fashion, CD39+ Tregs may be involved in the suppres-
sion of HIV-specific T-cell responses through the production of 
adenosine and consequent rise of cAMP in conventional T cells 
as shown by Nikolova et al (81). Similar to the PKA inhibitor 
experiment, it was demonstrated that the use of adenosine deami-
nase that hydrolyzes adenosine permits to revert the inhibition 
of immune responses and enhances the HIV-1-specific effector 
responses in an ex vivo model (115). On the other hand, Tregs 
could exert a direct inhibition of HIV infection and replication 
in conventional T cells by cell-to-cell contact. This mechanism is 
cAMP dependent and involved the PKA activation pathway (84). 
Therefore, cAMP may also play a positive role by inhibiting viral 
replication. In fact, there are a number of examples illustrating 
cAMP benefits; Banas et al. showed in infected monocytes and 
T-cell lines that the elevation of intracellular cAMP activates 
CREB protein that will compete for limiting amounts of CBP/
p300 thereby mediating a repressive effect on HIV LTR/enhancer 
transcriptional activity (116). Furthermore, the use of rolipram, a 
PDE4 inhibitor, prevented the degradation of cAMP consequently 
inhibiting the transcription of the genes under the control of 
HIV-LTRs (117, 118). Interestingly, the blockage of PDE4 activity 
also prevented the nuclear import of HIV DNA in memory T cells 
(118). cAMP may also limit viral infection by modulating the 
expression of the T-cell coreceptors needed for viral entry, indeed 
it was shown a downregulation of CCR5 and CXCR4 in a T-cell 
line using an agonistic-like anti-A2AR mAb that activated the 
cAMP/PKA pathway (119). Summing up, cAMP seems to play 
an important role on preventing HIV entry, DNA nuclear import, 
viral transcription, and viral replication. All this highlights the 
beneficial role of Treg on limiting HIV infection in conventional 
T cells since they remove ATP by generating adenosine and 
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transfer high amounts of cAMP to non-Tregs through GJICs that 
subsequently limit HIV replication.
CTLA-4
CTLA-4 is a negative immune-modulator receptor of the CD28 
superfamily of immune-regulatory molecules (such as CD80 or 
CD86) expressed in Tregs and with clear involvement in HIV dis-
ease. Its suppressive mechanisms have been extensively studied 
(14–17). Of note are Sakaguchi’s findings, where he demonstrated 
that nTreg-specific CTLA-4 deficiency or CTLA-4 blockade using 
anti-CTLA-4, impaired or abrogated nTreg-suppressive function 
in vivo and in vitro, respectively (14, 16). This is possible since 
nTreg will interact through CTLA-4 with activated or CD80/
CD86 expressing conventional CD4+ T cells and/or APCs, thus 
mediating suppression. It is claimed that such interaction may act 
synergistically with expression of ICER in conventional T cells 
mediated by Treg (12). On the other hand, CTLA-4 has been 
proved to be selectively upregulated in HIV-specific CD4+ T cells 
in HIV-infected patients, and its expression correlated positively 
with disease progression (49). Interestingly, HIV-gp120 protein 
enhanced Treg-mediated suppression through CTLA-4 upregula-
tion (114). Such enhancement is probably mediated by cAMP/
PKA pathway since cAMP itself was shown to induce CTLA-4 
upregulation in the absence of full T-cell activation (120). In 
fact, it could be reasonable to assume that CTLA-4 may syner-
gize with ICER since it will be also upregulated due to cAMP/
PKA downstream activation. However, despite the evidence 
of CTLA-4 involvement in HIV infection, other study showed 
that blocking CTLA-4 with an anti-CTLA-4 antibody did not 
demonstrated any differences in the frequency of HIV-p24gag-
conventional T cells when these cells were co-cultured with Treg 
(84). Therefore, CTLA-4 might not play a major role in the Treg-
suppressive activity in HIV infection. Taking all this information 
together, CTLA-4 would not act directly on the HIV replication, 
but would act through the suppression of HIV-specific CD4+ 
and CD8+ T cells function. Additionally, the presence of HIV 
or cAMP that induces CTLA-4 expression at the surface of Treg 
would increment this capacity.
Hiv iNFeCTiON iMPAiRS Treg ACTiviTY
Susceptibility of Treg to infection
Tregs express HIV-coreceptors CCR5 or CXCR4 at levels compa-
rable to other CD4+ T cells (79), which renders Treg susceptible 
to HIV infection (36, 37, 121–123). Furthermore, naïve Tregs are 
capable of upregulating the membrane expression of CXCR4 and 
CCR5 upon TCR stimulation (122), increasing their susceptibil-
ity to infection. The two viral strains CXCR4 and CCR5-tropic 
HIV showed differential infection dynamics. We described 
in vitro that CXCR4 virus produce a stronger deregulation than 
CCR5-HIV in both phenotype and functionality when Tregs are 
infected (36). Other studies report that HIV-CCR5 infects Tregs 
at lower levels compared to Teff at both early and late points (121). 
By contrast, Tregs were more efficiently infected with CXCR4 
strain compared to Teff at early time points, but the difference 
cleared at later time points of the virus life cycle (121). Whether 
Tregs constitute a major target for HIV or if they are more sus-
ceptible than conventional T cells to infection has been a matter 
of debate in the past years. However, recent in vivo studies have 
shown that circulating Tregs are not preferentially infected by 
HIV compared with effector T cells (121), in fact HIV infection 
induces deep cellular deregulation in CD4+ T cells, including 
the Treg subset. The HIV-mediated Treg deregulation affects the 
cell number, their phenotype, and functionality. During chronic 
HIV infection, the absolute Treg numbers in peripheral blood 
decline (40) even though the Treg frequency among the total 
CD4+ T-cell population is increased. In addition, our group has 
described that direct HIV infection of Tregs modifies the Treg 
phenotype and induces a strong impairment in their suppres-
sive capacity (36). A similar outcome was observed in a study 
of HIV-infected patients with immune reconstitution disease 
after ART, they described that Treg exhibited reduced immu-
nosuppressive capacity that was associated with over-active 
CD4+ T-cell responses (124). We also demonstrated in vivo an 
impaired capacity of Tregs to keep the balance between Treg/
IL-2-producing cells in viremic HIV-infected patients due to 
direct Treg viral infection (37), and probably contributing to the 
immune hyperactivation observed in HIV patients.
These findings provide clarifying information to the debate 
concerning the beneficial versus the detrimental role of Tregs in 
HIV infection. Since the Treg number and function is impaired 
in the presence of HIV, the negative impact on the HIV-specific 
responses might be limited. However, Treg impairment has 
probably a higher impact in the absence of an adequate control 
of immune hyperactivation, which at present is the major factor 
related to the HIV disease progression in infected patients.
Hiv Downregulates Foxp3 expression and 
impairs the Suppressive Activity of Treg
We demonstrated that HIV infection of Treg modifies its pheno-
type and functionality through a process mediated by intrinsic 
methylation mechanisms (36), possibly in a Treg attempt to 
protect its genome against the expression of foreign DNA (125). 
Foxp3 gene expression is strongly downregulated in HIV-
infected Treg, notably with CXCR4-tropic HIV, due to general 
increase in the CpG methylation pattern of two regulatory sites 
critical for Foxp3 expression in Tregs (36). It is known that DNA 
methylation in Treg can be addressed to two known DNA methyl 
transferases (DNMT1 and DNMT3b), since binding sites for 
DNMT1 and DNMT3b have been detected in Foxp3 locus (126). 
Interestingly, we have shown that the expression of DNMT3b 
was upregulated in HIV-infected Treg compared to non-infected 
Treg (36). Therefore, the DNMT3b increase might be responsible 
for the de novo methylation observed in Foxp3 promoter and, 
thus, be responsible for the subsequent downregulation of Foxp3 
expression observed in vitro in HIV-infected Treg (36).
As already described, Foxp3 expression is critical for Treg-
suppressive function (127). It was shown that in  vitro HIV-
infected Treg were less capable of suppressing the proliferation of 
T-effector cells in co-culture experiments (36, 128). These results 
support the impaired Treg-suppressive capacity that we observed 
in untreated HIV patients with high viral load (unpublished data). 
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However, other studies claim that HIV does not impair Treg-
suppressive function in patients (35, 129, 130) probably because 
they studied it in chronic infected patients, and it is known that 
the number of infected Treg is very low at the late stage of infec-
tion (121). Interestingly, the treatment of HIV-infected Treg with 
antiretroviral drugs, such as ZDV or T20, in vitro reverted the 
impairment of suppression since the loss of Foxp3 expression was 
avoided (36). Therefore, it seems that the Foxp3 downregulation 
may contribute to the Treg loss of suppressive function upon HIV 
infection. There are many suppressive mechanisms on Tregs sus-
ceptible to be affected by Foxp3 reduction as described previously. 
Foxp3 downregulation may have critical consequences on Foxp3-
transcriptional program, being PDE3B gene the most repressed 
by Foxp3 (60, 127); therefore, its repression might be abrogated if 
Foxp3 is downregulated and could have detrimental effects upon 
Treg. In fact, it was shown by Gavin et  al. that retroviral gene 
transfer and expression of PDE3B into Tregs was deleterious to 
Treg homeostasis (127). Such detrimental effect consisted in a 
significant reduction of PDE3B-expressing Treg numbers due to 
cell death or inefficient expansion, and it is most probably related 
to decreased cAMP intracellular levels due to its degradation by 
PDE3B (127). Other mechanism related to Foxp3 repression is 
associated with miR-142-3p transcriptional regulation (131). 
Foxp3 downregulates the miR-142-3p in order to keep the AC9/
cAMP active in Treg since miR-142-3p was described to target 
AC isoform 9 expression, thus, reducing the intracellular cAMP 
levels. Therefore, downregulation of Foxp3 expression will lead 
to miR-142-3p expression and this will have an indirect effect 
on Treg cAMP levels. Therefore, miR-142-3p might potentially 
contribute to the decrease in Treg absolute numbers and Treg 
function impairment shown in HIV, associated with the inability 
to maintain high cAMP levels. Besides this mechanisms affecting 
overall cAMP levels, it has been shown that the repression of 
Foxp3 using siRNA in hepatocellular carcinoma patients induces 
a downregulation of CTLA-4 in those Treg with lower Foxp3 lev-
els, compromising their function (132). Thus, similar outcomes 
may be expected from HIV-infected Treg whose Foxp3 gene is 
downregulated.
Besides transcriptional regulation, it is known that Foxp3 can 
also be regulated by various post-translational modifications, 
such as acetylation, ubiquitination, and phosphorylation, thus 
affecting its activity (133, 134). A decade ago, Li et al. and others 
showed that the transcriptional repression by Foxp3 involves a 
histone acetyltransferase (HAT) complex that includes HAT 
TIP60 and class II histone deacetylase 7 (HDAC7) (135, 136). 
Within this complex, TIP60 is the principal responsible for Foxp3 
acetylation and Foxp3-mediated transcriptional regulation via 
STAT3 in vivo (136). Therefore, the association of HDAC7 and 
TIP60 to the Foxp3 N-terminal domain resulted to be a require-
ment for Foxp3-mediated transcriptional repression in terms of 
suppression of IL-2 production in T cells after TCR stimulation 
(136). In the same line as the previous comment, there are a num-
ber of animal models such as the TIP60 conditional knock out 
mice supporting the relevance of Foxp3 complex formation (133). 
Indeed, several studies showed that the failure of Foxp3 to associ-
ate with TIP60 and HDAC7 leads to altered Foxp3-dependent 
transcription (higher promoter activity and production of IL-2) 
and epigenetic modifications, limiting nTreg function at inflam-
matory sites and decreasing the Treg population in peripheral 
immune organs, consequently resulting in accelerated fatal 
autoimmune disease (133, 136, 137).
In terms of HIV infection, it has been shown that HIV-1 
transactivator Tat protein represses TIP60 activity (138). Indeed, 
Tat induces the poly-ubiquitination and, thus, the degradation 
of TIP60 by the p300/CBP-associated E4-type ubiquitin-ligase 
activity (139), consequently affecting the Foxp3–TIP60–HDAC7 
complex formation. Therefore, it could be expected a limited Treg 
function or decreased Treg levels as shown in the animal models 
(133, 137) (See Figure 1). In fact, the HIV-dependent disruption 
of Foxp3 complex may be contributing to the low Treg absolute 
numbers detected in HIV patients (140, 141).
Finally, HIV infection also leads to a disturbance on inter-
leukin secretion profile (36) probably associated with Foxp3 
downregulation (48, 142). Indeed, HIV-infected Tregs have 
shown a significant increase in IL-4 production and a decrease 
in TGF-β production (36). Since Foxp3 has a deep influence on 
Treg-associated genes expression (62) and that Foxp3 expression 
is highly modified during HIV infection (36), we can assume 
that such dysregulation in the production of cytokines may affect 
Treg function, since this dysregulation correlates with Treg switch 
to a T helper type 2 cytokine profile that may contribute to the 
hyperactivation shown in HIV patients.
impaired Balance between Regulatory  
T Cells and iL-2 Producing CD4+ T Cells 
in Hiv infection
The preserved and constant ratio between Treg and the number of 
activated T cells constitutes a homeostatic mechanism ensuring 
that T-cell activation and expansion remain under control (41). 
However, the persistent immune hyperactivation that drives HIV 
disease suggest that there is a dysfunction on such mechanism, 
since the Treg values are decreased despite high levels of activated 
T cells (34, 123, 140). In fact, a recent study indicates that the bal-
ance between Treg and IL-2 producing T-cell numbers is deeply 
disturbed in viremic HIV-infected patients (37). Such balance 
impairment is motivated by a HIV-mediated downregulation of 
IL-2 receptor alpha (CD25) at the surface of Treg from viremic 
patients, as confirmed by in vitro experiments of Treg infection 
with HIV (37). Therefore, the lower expression of CD25 observed 
in Treg from infected patients could affect their capacity of expan-
sion due to the impossibility of responding to extracellular IL-2 
produced by effector CD4+ T cells. Furthermore, decreased 
CD25 expression may also reduce Treg-suppressive function. 
Indeed, it has been reported in healthy donors that a lower 
CD25 expression correlates with impaired suppressive capacity 
and lower capability to maintain Foxp3 expression (143). CD25 
downregulation correlates with the reduction of STAT5 activation 
in HIV-infected Treg (37), being STAT5 a key player on CD25 
activation downstream cascade. Loss of phospho-STAT5 has 
been shown to abrogate Treg-suppressive activity and to induce 
the downregulation of Foxp3 expression (144). STAT5 and CD25 
genes contain differentially methylated regions, and many of 
these regions present DNA methylation-dependent enhancer 
FiGURe 1 | Treg suppressor mechanisms and Hiv-dependent Treg dysregulation.
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activity (145). Therefore, STAT5 and CD25 expression could 
be controlled by DNA methylation as occurs with Foxp3, thus 
explaining their downregulation upon infection. Therefore, the 
downregulation of Foxp3 expression, the functional impairment 
of Treg (36), and the impairment of CD25 pathway (37) observed 
in Treg from infected patients could be critical in the immune 
hyperactivation that hallmarks HIV disease.
Hiv Modifies the Treg Cellular 
Transcriptome Following infection
It was shown by using an ultrasensitive multiplexed NanoString 
gene expression assay that HIV-1 modifies the Treg transcrip-
tome after infection (128). Infected and non-infected Treg 
formed two distinct clusters showing differential expression in a 
total of 23 genes (128). HIV-infected Tregs show downregulation 
of genes linked to TCR signaling (PTPRC, TCR, IKBKE, CD3E), 
which may affect Treg antigen recognition and activation, and 
CD27 and PPAR-gamma that are related to suppressor function 
and enhancement of Treg function, respectively (146, 147). 
Furthermore, many other genes involved in function and Treg 
lineage were downregulated (TRAF6, STAT5, ETS-1, LEF-1) 
(148–151) but also Treg function inhibitor genes were upregu-
lated after infection (LTA; IL-18RAP, BCL6, IL-7) (152–155), 
probably contributing to the HIV-dependent Treg impairment. 
Moreover, LEF-1, a gene that contributes together with Foxp3 
in controlling transcription in Treg (151), and STAT5a, essential 
for Foxp3 expression, were downregulated (36, 46). However, in 
the Angin et al. study, Foxp3 downregulation was not detected 
and suggested a possible destabilization of the master transcrip-
tion factor by downregulation of ETS-1 (148). Despite of these 
results, in recent years, we have shown that indeed HIV infec-
tion downregulates Foxp3 expression (36). Summing up, HIV-1 
infection seems to exert Treg deregulation through a number of 
pathways simultaneously. The transcription pattern modifica-
tion of critical genes involved in Treg function will probably 
play a detrimental role allowing HIV-1 hyperactivation and 
pathogenesis.
MeCHANiSM SUMMARY
In Figure 1, we have gathered most of the Treg suppressor mecha-
nisms covered in the review and how HIV-dependent dysregula-
tion of Foxp3, CD25, and STAT5 may hinder Treg function.
Upon viral entry and replication (Figure  1 ①), HIV-1 Tat 
protein induces the poly-ubiquitination and degradation of 
TIP60, consequently disrupting the Foxp3–TIP60–HDAC7 
complex formation, critical for Foxp3 function. Furthermore, 
Tregs suffer a downregulation of CD25 expression and, hence, 
a reduction in phosphorylated STAT5 levels. Additionally, HIV 
infection leads to DNMT3b upregulation, this methylase will 
methylate two regulatory sites critical for Foxp3 expression, 
inhibiting Foxp3. Moreover, STAT5 is essential to sustain Foxp3 
expression, its downregulation further compromises Foxp3 level. 
With a reduced expression of Foxp3 (Figure 1 ②), miR142-3p and 
PDE3B expression will not be downregulated; therefore, PDE3B 
will start to degrade intracellular cAMP and miR142-3p will block 
AC9 mRNA, inhibiting cAMP production. Furthermore, Foxp3 
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induces CD39 gene expression; therefore, the lack of Foxp3 could 
result in decreased levels of CD39 and, hence, lower conversion 
of extracellular ATP to adenosine (Figure  1 ③). Low levels of 
extracellular adenosine will result in decreased signaling through 
A2AR and, hence, less induction of AC activity and lower cAMP 
production in either Tregs or conventional T cells. After viral 
infection, Treg may not be able to maintain their cAMP supra-
physiological levels (Figure 1 ④), hence transferring less cAMP 
to conventional T cells through GJICs compared to optimal 
conditions. Insufficient cAMP levels in conventional T cells upon 
cellular contact, together with the decreased endogenous produc-
tion of cAMP (Figure 1 ⑤), will result in lower ICER production 
via PKA activation and, therefore, NFAT will maintain the induc-
tion of pro-inflammatory cytokines, such as IL-2. NFAT will also 
bind to HIV-promoter enhancing HIV genes transcription. HIV-
infected Treg may not only be unable to suppress the activity and 
IL-2 production by conventional T cells, but also will not be able 
to sense an increase in extracellular IL-2 levels as a result of T-cell 
hyperactivation (Treg CD25 is downregulated), thus impairing 
Treg proliferation and suppressive response. In addition, CD25 
downregulation renders Treg less capable of consuming IL-2, this 
means higher IL-2 availability for conventional T cells. IL-2 cap-
tured by conventional T cells induces activation of PDE and AC7 
downregulation, thus leading to intracellular cAMP degradation. 
Low intracellular cAMP is related to increased T-cells prolifera-
tion and activation. As a result of these HIV-mediated alterations 
of regulatory mechanisms, the balance between activated T cells 
and Treg will be broken, compromising the homeostatic fine-
tuned balance of the immune system.
CONCLUDiNG ReMARKS
Retroviruses, such as HIV, have coexisted with the human race 
for millions of years. By that, host species have evolved to protect 
themselves by different mechanisms, such as restriction factors, 
but also by modulating the immune system to reach a fine-tuned 
response against the virus and other pathogens. As a consequence, 
virus counter-evolution leads to an evolutionary arms race. This 
phenomenon is well illustrated in Leigh Van Valens’s Red Queen 
Hypothesis, where two evolutionary systems, such as host/patho-
gen are constantly developing in order to maintain its fitness rela-
tive to the system they are co-evolving with. In this review it has 
been described how Treg exert a number of immune-modulatory 
mechanisms capable of hindering viral entry, replication and 
transcription but also guaranteeing the immune system homeo-
stasis. However, HIV is capable of infecting and abrogating Treg 
function by inducing the downregulation of key molecules essen-
tial to enable Treg-dependent suppression. Impairment of Treg 
immune-modulatory function and induction of hyper-immune 
activation, provide an immunological condition favorable for 
viral infection and replication. The fact that HIV might exert a 
suppressive effect upon Treg function help us to understand that 
Treg role might be detrimental for HIV fitness and disease pro-
gression. This hypothesis means that the beneficial role of Treg on 
preventing immune hyperactivation outweighs the detrimental 
effect of Treg upon HIV CD4+ and CD8+-specific responses, 
which has been a matter of controversy in recent years. Up to date, 
it has been extensively described by others the pros and cons of 
Treg immunomodulatory mechanisms in HIV-infected patients 
and its effect upon disease progression. However, the increasing 
evidence of HIV’s direct impact upon the Treg population adds 
an additional layer of complexity considering the dysregulation 
of HIV-infected Treg and the contribution of such alterations to 
the disease progression. Understanding the immune-regulatory 
mechanisms that are impaired or deregulated will facilitate to 
unveil the rationale behind the immune hyperactivation that hall-
marks HIV disease. This will open new avenues to find potential 
targets that could restore the immune homeostasis and, hence, 
decrease the systemic immune activation and exhaustion that 
determine the disease progression.
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